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Abstract 
Peripheral precocious puberty results from peripheral production of sex steroids independent of activation 
of the hypothalamic-pituitary gonadal axis. It is much less common than central precocious puberty. 
Causes are variable and can be congenital or acquired. In this review, we will discuss the diagnosis and 
management of the most common etiologies including congenital adrenal hyperplasia, McCune Albright 
syndrome, familial male-limited precocious puberty, and adrenal and gonadal tumors. 
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Introduction 
Peripheral precocious puberty (PPP) refers to conditions in which early puberty occurs as a result of sex 
steroid production from gonadal and extra gonadal sources independent of gonadotropin stimulation.  
PPP is much less common than CPP, and may be congenital or acquired. Unlike in CPP, the type of 
secondary sexual development, rate of progression and sequence of pubertal events in PPP may be 
strikingly different from that seen in normally-timed puberty.  
In this review, we will describe the most frequently encountered etiologies of PPP including congenital 
adrenal hyperplasia (CAH), McCune Albright syndrome (MAS), Familial male-limited precocious puberty 
(FMPP), and sex steroid secreting tumors. 
1- Congenital Adrenal Hyperplasia: 
CAH is a family of autosomal recessive diseases of abnormal cortisol biosynthesis, which is commonly 
associated with disordered puberty (1). 
Several enzymatic defects are associated with CAH and are highlighted in Figure 1. Clinical 
manifestations depend on the enzyme involved, type of mutation and the hormone that is overproduced 
or deficient.  Of all causes of CAH, 21 hydroxylase (21OHase) deficiency is the most common followed by 
11 beta hydroxylase (11OHase) deficiency, and 3 beta hydroxysteroid dehydrogenase (3ßHSD) 
deficiency. Other less common forms of CAH include p450oxidoreductase deficiency, 17hydroxylase 
deficiency and lipoid CAH (StAR deficiency). In this review, we will focus on CAH due to 21OHase 
deficiency which is the most common cause of PPP. 
A- CAH due to 21OHase deficiency 
The most common cause of CAH, 21OHase deficiency accounts for more than 90% of affected 
individuals (2, 3), and has a worldwide incidence of 1 in ~15,000 livebirths. CAH due to 21OHase 
deficiency results from alterations in the highly homologous p450c21 genes which consist of an inactive 
pseudogene (CYP21A1 or CYP21P) and an active gene (CYP21A2 or CYP21), both located in a small 
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region on chromosome 6p21.3 (4, 5). Approximately 75% of mutations are due to recombination events 
between the inactive and active genes, resulting in gene conversions. However, a multitude of other 
molecular genetic abnormalities involving CYP21A also occur.  
The 21 OHase enzyme is involved in the cortisol and mineralocorticoid pathways, and propels the 
conversion of 17 hydroxyprogesterone to 11 deoxycortisol and progesterone to deoxycorticosterone. 
Cortisol deficiency stimulates ACTH secretion which in turn drives the production of androgens (DHEA 
and androstenedione) due to a build-up of precursors proximal to the block in the glucocorticoid pathway. 
These 2 androgens are converted to testosterone and cause signs of virilization which is the clinical 
hallmark of CAH due to 21 OHase deficiency.  
The clinical manifestations of 21OHase deficiency may be broadly divided into 3 different categories: the 
classic salt wasting, the classic non salt wasting or simple virilizing and the nonclassic form. Classic 
21OHase deficiency results from a combination of 2 severe gene mutations, whereas individuals with the 
nonclassic form are compound heterozygotes, having one severe mutation and one mild mutation or are 
homozygous with 2 mild gene mutations. The majority of children with classic CAH are salt wasting. The 
nonclassic form is one of the most common autosomal recessive diseases, with a higher prevalence in 
certain ethnic groups specifically Eastern European Jews, Yugoslavs, Mediterranean and Hispanics (6).  
Clinical manifestations: 
In line with its molecular genetic heterogeneity, the phenotype of individuals with 21OHase deficiency 
exists within a broad spectrum. Females with the classic form present with ambiguous genitalia with 
variable degrees of virilization, ranging from isolated clitoromegaly to male-appearing external genitalia 
but without palpable testes, as seen in figure 2. Internal genitalia include normal ovaries and uterus. 
Under the effect of excess androgens, the urethra and vagina may share a common channel internally 
resulting in a single perineal opening known as a urogenital sinus. Males with the salt-wasting form who 
are not identified by neonatal screening typically present with failure to thrive, and an adrenal crisis 
between 1 and 2 weeks of life. Their external genitalia appear normal, with the exception of some skin 
hyperpigmentation. 
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Postnatally, children may develop pubic and axillary hair, acne, and early adult body odor. If inadequately 
controlled, the excess androgens can cause rapid linear growth and advancement in skeletal maturation 
which may eventually impair height potential and cause short stature.  A meta-analysis from 18 centers 
showed that the mean adult height (AH) of patients with classic CAH was 1.4 standard deviations (10 cm) 
below the population mean (7). Secondary CPP may complicate CAH and further compromise AH (8) 
particularly in patients with poor control.  
During adolescence and adulthood, affected girls and women may develop hirsutism, significant acne, 
irregular menses, amenorrhea, and infertility, in a picture similar to polycystic ovary syndrome (9, 10). 
Additional signs of androgen excess such as increased muscle mass and deepening of the voice may 
develop, particularly in the setting of non-compliance. Decreased fertility resulting from chronic 
anovulation and endometrial dysfunction have been described in women with classic and nonclassic CAH 
owing to excess androgen secretion which alters the hypothalamic pituitary gonadal axis and affects 
ovarian function directly (11). Similarly, low fertility rates are described in men with CAH, with testicular 
adrenal rest tumors (TART) being the most common cause (12, 13). TARTs are benign tumors 
resembling adrenocortical tissue, which are typically found in the rete testis and thought to cause 
mechanical oligospermia or azoospermia via obstruction of the terminal seminiferous tubules. There is 
evidence to suggest that cells in TARTs derive from totipotent embryonic cells that resemble fetal Leydig 
cells. These cells have ACTH and LH receptors and stimulation by both hormones at various stages in life 
can lead to TART formation (14). 
Diagnosis 
Girls and boys with nonclassic CAH due to 21 OHase deficiency may present in childhood with premature 
pubarche and other signs of androgen excess. Young women may present with hirsutism and menstrual 
irregularities. 
A very high random serum 17-hydroxyprogesterone level of >3500 ng/dL and typically > 10,000 ng/dl is 
diagnostic of classic CAH. Lower levels are seen in nonclassic forms with a 17-hydroxyprogesterone level 
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of >1500 ng/dl being diagnostic (1, 15). In patients with borderline results, an ACTH stimulation test may 
be necessary.  
In children with clinical signs of CPP, a GnRH stimulation test may be necessary to confirm this diagnosis. 
Treatment 
• The treatment of 21OHase deficiency is aimed at suppressing adrenal androgen production while 
avoiding overtreatment with glucocorticoids which may lead to decreased linear growth. While 
hydrocortisone is believed to have the least deleterious effect on growth, a wide range of 
individual sensitivity to different forms of glucocorticoids has been demonstrated (16). Children 
with salt wasting CAH also require mineralocorticoid replacement as well as salt supplementation 
during the first few years of life.  
• Although early genital surgery is an area of controversy (17), vaginoplasty and clitoral recession 
are often opted for by parents of girls with severe manifestations of classic CAH (18). With 
extremely rare exceptions, a female sex assignment is considered standard of care (2). While a 
female gender identity is the norm, girls with classic 21OHase deficiency exhibit an increase in 
“boy-typical” behavior, toy preferences and cognitive abilities (19).  
• Children with nonclassic CAH may require treatment with a glucocorticoid if they have significant 
signs of virilization or bone age (BA) advancement.  
• Intensifying glucocorticoid treatment is the mainstay medical treatment for men or women with 
CAH and impaired fertility. 
• In children with evidence of CPP, treatment with a GnRH analog (GnRHa) may be added to 
improve AH. Several small case series of children with CAH and CPP showed regression in 
breast development and testicular volume, decreased BA advancement and linear growth velocity 
and improved growth potential with GnRHa treatment (8, 20). Treatment should be started early 
and appears to be more beneficial in those whose BA is not significantly advanced (21). 
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• Although not considered standard of care, a few small studies have suggested that the addition of 
growth hormone (GH) treatment to a GnRHa may further augment preservation of height potential 
in these patients (22, 23). 
2- McCune Albright syndrome 
McCune Albright syndrome (MAS) is a rare cause of PPP, and is a sporadic condition caused by post-
zygotic activating mutations in the GNAS1 gene on chromosome 20 (24). The gene encodes the alpha 
subunit of G-protein (Gsα), a receptor mediator which stimulates intracellular cyclic AMP formation. 
Activating mutations lead to autonomous hyperfunction of several endocrine and non-endocrine tissues 
(25). In addition to PPP, endocrine manifestations that can be present in variable combinations in MAS 
include growth hormone excess, hyperthyroidism, cortisol excess, hyperprolactinemia and 
hypophosphatemia.  
PPP is the most common endocrine manifestation, and occurs more frequently in girls in whom it is 
almost invariably the presenting feature of the disease (26).  
Classically described as the triad of PP, fibrous dysplasia of bones, and café-au-lait macules, MAS is now 
recognized as a heterogenous condition with a spectrum of findings resulting from variable tissue 
distribution of the mutation. The café au lait macules in MAS have irregular borders (coast of Maine) in 
contrast to the café au lait macules of neurofibromatosis which have smooth borders (coast of California). 
They typically follow the developmental lines of Blaschko and do not cross the midline, as seen in figure 
3. 
PPP in girls results from the production of high levels of estrogens by autonomously functioning unilateral 
ovarian cysts.  
Clinical signs resulting from estrogen exposure include breast development, estrogenization of the 
vaginal mucosa, accelerated linear growth and vaginal bleeding which results from withdrawal of estrogen 
when the cyst resolves. Vaginal bleeding without breast development may be the only manifestation, 
which can occur if a cyst rapidly develops and involutes. 
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The clinical course of girls with MAS and PPP is variable with some girls experiencing vaginal bleeding 
once with no further episodes, and others having recurrent cysts at unpredictable intervals. Girls with 
recurrent cysts may experience accelerated linear growth and BA advancement leading to a decrease in 
final AH. Therefore a period of observation after a first episode of bleeding is necessary, and treatment 
should be reserved for those with a progressive form of PPP. Secondary CPP may complicate the course 
of the disease especially in girls with a significantly advanced BA. The differentiation of CPP from PPP 
based on clinical features may be difficult in this instance, and a GnRH stimulation test may be 
necessary. An LH peak of 4-6 mIU/ml in response to GnRH stimulation confirms CPP. 
Many girls with MAS continue to have irregular menstrual bleeding in adulthood due to persistent 
autonomous ovarian function. However, long term data suggest that these women have successful 
spontaneous pregnancies despite a longer than average time to conception (27).  Menstrual regulation 
can be achieved with combined oral contraceptive pills or with progestin only containing pills or 
intrauterine device. 
PPP occurs less commonly in boys compared to girls.  In a study of 54 males with MAS, PPP was 
present in 21% of patients resulting from constitutive activation of Gsα leading to increased production of 
testosterone. The most common histopathological finding was Leydig cell hyperplasia, which can be 
unilateral. Germ cell tumor was diagnosed in one patient. Abnormal ultrasound findings were present in 
81% of patients, and included hyperechoic lesions (49%), hypoechoic lesions (30%), microlithiasis (30%), 
heterogeneity (47%) and focal calcifications (11%). These findings suggest that while PPP is not common 
in boys with MAS, the incidence of gonadal pathology is similar between boys and girls (28).  
Macroorchidism is commonly seen and was reported in 44% of patients with MAS, half of whom were 
children, and was more commonly bilateral (28). The presence of macroorchidism in children with MAS 
poses a special diagnostic challenge especially in the presence of signs of puberty, as it can result from 
CPP or PPP. Alternatively, Sertoli-cell only GNAS1 mutations have been reported as a cause of 
macroorchidism in boys with MAS, further complicating the diagnostic process (29). Additional testing in 
the form of a GnRH stimulation test may be necessary in this setting. The co-existence of PPP and GH 
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excess can result in particularly rapid linear growth and coarsening of the facial features. Thus, it is 
important to maintain vigilance regarding additional potential manifestations of MAS during routine follow 
up.  
Testicular ultrasound and serial exams are recommended for all males with MAS, with close observation 
and serial imaging if lesions without local invasions are noted. Surgical intervention should be reserved 
for palpable, rapidly growing or locally invasive lesions due to risk for malignant degeneration of some 
lesions (28). While microlithiasis is a common finding in boys with MAS, it is unclear if it leads to 
increased neoplastic transformation (30). 
Diagnosis 
In girls with clinical features suggestive of MAS, an elevated serum estradiol level and suppressed 
gonadotropins confirms the diagnosis of PPP. A pelvic ultrasound typically reveals a large unilateral 
ovarian cyst. Occasionally, a hemorrhagic cyst may be mistaken for a tumor leading to unnecessary 
oophorectomy (31).  
Once the diagnosis of MAS is made, a bone scan should be obtained to evaluate for associated fibrous 
dysplasia lesions, and laboratory testing should be performed to assess for other associated endocrine 
hyperfunction. 
While genetic testing for GNAS1 gene mutations is commercially available, the yield is low due to the 
mosaic distribution of the mutation and the fact that it may be limited to specific tissues and is frequently 
not detected in peripheral blood. Thus, the diagnosis of MAS remains a clinical one. 
Treatment 
• Surgical resection of the ovarian cyst or oophorectomy is not recommended for the treatment of 
PPP in girls with MAS, due to a negative impact on fertility and the potential for recurrence of 
cysts in remaining ovarian tissue. 
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• Medical treatment should be reserved for girls with recurrent ovarian cysts associated with 
frequent episodes of vaginal bleeding and advanced BA leading to compromised AH, keeping in 
mind that height predictions and assessment of linear growth can be complicated by the 
concomitant presence of hyperthyroidism, GH excess, or fibrous dysplasia . Additionally, extreme 
fluctuations in estradiol levels are common and the BA can advance rapidly, adding to the 
challenge of the management of this complex condition. Therefore, the decision to treat should be 
individualized and a period of close observation for frequency of menstrual bleeding, linear 
growth velocity and rate of BA advancement may be necessary initially, and periodic surveillance 
for associated endocrinopathies that can affect growth will be important. 
• Various pharmacologic interventions have been studied. Historically, progestins such as 
medroxyprogesterone acetate and anti-androgens such as cyproterone acetate were attempted 
but found to be ineffective (Table 1). Ketoconazole, a nonspecific p450 inhibitor of adrenal and 
gonadal steroidogenesis has also been tried.  While it results in cessation of menses and 
regression of pubertal signs (32), there are concerns about its long term safety and potential for 
adrenal insufficiency and hepatotoxicity (33).   
• More recent medical interventions have been aimed at decreasing estrogen production with 
aromatase inhibitors (AIs) or blocking the effect of estrogens at the end organ with estrogen 
receptor modulators.  
• AIs are a class of nonsteroidal competitive inhibitors of the p450 aromatase enzyme which 
catalyze the conversion of androgens to estrogens .While the first and second generation agents 
testolactone and fadrozole were tried in girls with MAS, they were ineffective (34, 35). Third 
generation agents such as anastrozole and letrozole have a higher potency and are better 
tolerated compared to earlier generation AIs. However, only letrozole has been demonstrated to 
have efficacy in the treatment of MAS (36-38). In a pilot study of 9 girls treated with letrozole, 
linear growth and BA advancement rates significantly decreased while menstrual bleeding 
ceased or decreased in frequency. However, an increase in mean ovarian volume and in cyst 
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size was noted, and one girl had a large ovarian cyst which resulted in torsion (38). Long term 
outcomes of 28 girls including the 9 girls from the initial pilot study treated with letrozole for up to 
10 years were published (37). Results showed a significant improvement in PAH, no adverse 
events, and no changes in uterine or ovarian volumes. 
• Tamoxifen was investigated in a prospective multicenter study of 25 girls with PPP and MAS 
treated for 1 year.  Episodes of vaginal bleeding decreased, linear growth slowed, and rates of 
skeletal maturation decreased. However, an increase in uterine volume was noted (39). In a 
retrospective study of 8 girls treated with tamoxifen for 3-8 years and followed for a mean period 
of 8.3 years, vaginal bleeding ceased and PAH increased (40). Reassuringly, no alteration in 
uterine volumes or endometrial thickness was noted.  
• Fulvestrant, a pure estrogen receptor antagonist, was studied in 30 girls with PPP related to MAS 
and found to be moderately effective and safe (41). However, the requirement for intramuscular 
injections is a distinct drawback to its use.  
• Table 1 summarizes the efficacy and safety of the different pharmacologic agents used for the 
treatment of PPP in girls with MAS. 
• Given the rarity of boys with MAS and PPP, treatment information is derived from case reports. 
Similar to the treatment approach in other forms of PPP in boys, the combination of anastrozole 
and the competitive androgen blocker bicalutamide has been reported and appears to be a 
promising treatment option for this rare condition (42). This combination treatment will be 
discussed further in the FMPP section.  
3- Familial male limited precocious puberty 
FMPP or testotoxicosis is a rare disorder caused by an activating mutation of the LH receptor resulting in 
autonomous Leydig cell secretion of testosterone, independent of gonadotropin stimulation (43, 44). 
Mutations can be de novo or inherited in an autosomal dominant fashion. Characteristically, patients have 
an elevated testosterone and suppressed gonadotropins and the clinical phenotype is limited to males. 
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Affected boys typically present before the age of 4 years with signs of virilization. Mild testicular 
enlargement is usually present. If left untreated, affected individuals will achieve significantly shorter AHs 
than expected for their genetic potential. Although pubertal progression is the norm, a case of FMPP 
characterized by intermittent spontaneous remission has also been reported (45). 
Secondary CPP can develop and complicate the picture, especially in boys with a significantly advanced 
BA (46).  
Despite reported oligospermia in a few men with FMPP, most retain normal fertility (47-49). Reports of 
one man with a seminoma (50) and a child with testicular nodular hyperplasia (51) should raise 
awareness of the possibility of the development of tumors in FMPP. 
Treatment 
Different pharmacological regimens have been used to treat boys with FMPP. Results of studies of 
medical treatment in FMPP are summarized in table 2. 
• Cyproterone acetate and medroxyprogesterone acetate were historically used in boys with FMPP 
but were minimally effective in preserving AH (52). 
• In contrast, ketoconazole has proven to be effective in the treatment of FMPP due to its ability to 
inhibit adrenal and gonadal steroidogenesis. However, there are safety concerns with 
ketoconazole which include liver toxicity and adrenal insufficiency and one case of  liver failure 
(53) has been reported.  
• Therefore, the most frequent approach currently involves the combination of an anti-androgen 
and an AI. The use of AI in the treatment of PPP stems from a recognition of the role of estrogen 
in epiphyseal fusion in boys and girls. A prospective study started in the 1990’s utilized 
spironolactone and testolactone, which was eventually replaced with anastrozole. Final AH in 
treated patients significantly exceeded predicted AH at treatment start (173.8 ± 6.9 vs 
164.9 ± 10.7 cm; P < .001) (54). Along the same lines, the combination of bicalutamide, a potent 
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selective androgen receptor inhibitor and a third generation AI was first tried in 2 patients and 
showed promising results laying the ground for additional studies (55). The BATT (Bicalutamide 
and Anastrozole Treatment of Testotoxicosis) study is a multicenter international prospective trial 
involving 13 patients with FMPP treated with bicalutamide (12.5-100mg daily) and anastrozole 
(0.5-1mg daily) for 1 year. Rates of growth and bone maturation decreased, with the ratio of BA to 
chronological age significantly declining from 2.1 ± 0.6 at baseline to 1.0 ± 0.4 at 1 year.  
Gynecomastia and breast tenderness were common occurring in 42.9% and 12.5% respectively 
(56). No long term results have been published for this study as of yet. However, results from a 
case report of 2 boys receiving this combination therapy (including letrozole in 1 patient) for up to 
5 years were promising (57). Given limited data on the use of letrozole in FMPP, it is difficult to 
assess its efficacy compared to anastrozole. 
4-Gonadal and adrenal tumors 
Gonadal and adrenal tumors are rare causes of PPP. As in other causes of PPP, the sequence of events 
in pubertal development is altered and the tempo of progression may be more rapid compared to CPP.  
A. Gonadal tumors 
Sex cord–stromal cell tumors and germ cell tumors (GCTs) are the two types of gonadal tumors that are 
commonly associated with endocrine manifestations.  
1-Sex cord-stromal tumors 
Juvenile granulosa cell tumors (JGCT) are the most common sex cord-stromal cell tumors in the pediatric 
population (58). PPP is seen in up to 70% of JGCT (59). Affected children may manifest signs of 
androgen and/ or estrogen exposure. JGCT can secrete inhibin and mullerian inhibitory substance both of 
which can be used as tumor markers. These tumors have a favorable prognosis and unilateral salpingo-
oophorectomy is considered curative. 
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Leydig cell tumors (LCT) are the most common hormone-producing tumors of the testes, and very rarely 
occur in the ovaries (60). Prepubertal boys present with signs of virilization and gynecomastia may 
occasionally be present due to estrogen production by the tumor or aromatization of testosterone to 
estrogen (61). Physical exam reveals asymmetric testes. Laboratory findings consist of elevated 
testosterone and suppressed gonadotropins. LCTs are typically benign in children and orchiectomy is 
considered curative (62). 
Leydig and Sertoli cell tumors occur frequently in patients with Peutz-Jeghers syndrome, in whom signs 
of PPP may be the presenting manifestations (63, 64). 
2-Germ cell tumors 
GCTs are the most common ovarian tumors in children but are extremely rare in the testes. They include 
dysgerminomas, teratomas, and embryonal carcinomas. GCTs cause PPP via secretion of hCG which 
acts at the LH receptor in gonadal tissue to stimulate sex steroid production.  
It is important to note that GCTs occur more commonly outside of the gonads, and PPP may be the only 
manifestation in this setting.  
Extra-gonadal GCTs occur more commonly in patients with Klinefelter syndrome, particularly in the 
mediastinum (65).  
An elevated serum β-HCG and/or α-fetoprotein level is characteristic of GCTs. However, these levels may 
be normal in CNS GCTs, and may only be elevated in CSF. Additionally, these tumors may be small and 
difficult to localize, posing additional challenges to making a diagnosis. Once treatment is started, serum 
testosterone level can be used as a tumor marker.  
 
B. Adrenal tumors 
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Adrenocortical tumors (ACT) are rare causes of PPP and account for less than 1% of all childhood 
malignancies. The majority of these tumors occur in children younger than 4 years of age. ACTs have a 
strong genetic basis and have been described in association with several genetic syndromes, such as Li-
Fraumeni syndrome, congenital hemihypertrophy, Beckwith-Wiedemann syndrome (BWS), MEN1, and 
Carney complex. Germline mutations of the p53 gene, a tumor suppressor gene, were later identified in 
these conditions, as well as in children with sporadic ACT (66, 67). The association of BWS and ACT has 
unraveled additional genetic etiologies. The overexpression of IGF2 and inactivation of the p57KIP2 
tumor suppressor gene resulting from genetic abnormalities at the 11p15 locus are implicated in the 
development of ACT. Mutations in additional tumor suppressor genes such as menin in MEN1, and 
PRKAR1A in Carney complex have also been described in association with ACT. Importantly, PPP is not 
specific to any of the mutations 
Histologically, ACTs consist of 2 subtypes; adenomas and carcinomas. Carcinomas are more common in 
children. Macroscopically, adenomas tend to be relatively small and well demarcated, whereas 
carcinomas tend to be large, lobulated and friable. Microscopic features such increased mitotic index, 
nuclear atypia and cellular pleiomorphism are associated with malignancy (68). 
Diagnosis 
The majority of ACT in children are functional and may autonomously oversecrete one or more of the 3 
major classes of corticosteroids and often secrete a mixture of these. The most common clinical 
manifestations are signs of virilization resulting from excessive androgen production. Based on a registry 
of 254 children, signs of virilization were present either alone or in association with signs of glucocorticoid 
excess in 84% of patients (69). Signs of glucocorticoid excess include rapid weight gain, round face, 
facial plethora, striae, hypertension, hirsutism and glucose intolerance.  
DHEA and DHEAS are the major androgens produced and can be used as tumor markers. Lab 
evaluation should also include testosterone as well as testing for cortisol excess if cushingoid features are 
present. Mineralocorticoid excess is rare and testing should be reserved for patients with suspicious 
clinical features. 
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Treatment 
Complete surgical resection is the cornerstone of successful treatment, and results in an excellent 
prognosis whereas patients with unresectable disease have a dismal outcome (70). Once the tumor is 
resected, sex hormone levels rapidly decrease leading to regression of secondary signs of puberty. 
However, prolonged exposure to sex steroids can lead to activation of the HPG axis and CPP 
necessitating treatment with a GnRHa. 
Conclusion 
PPP is a heterogenous condition resulting from excess sex steroid production from gonadal or extra 
gonadal sources, independent of gonadotropin stimulation. The most common condition associated with 
PPP is CAH, which is usually due to 21 OHase deficiency resulting in excess androgen production.  
While there is no standardized treatment for PPP in MAS, benefit may be obtained from letrozole or 
tamoxifen. Sex steroid producing ovarian tumors are rare, with JGCT being the most common. In boys, 
gonadal causes include FMPP and gonadal tumors, most commonly LCTs. Combination therapy with an 
anti-androgen and AI improves signs of virilization, and decreases rates of growth and skeletal maturation 
in boys with FMPP. 
Practice Points: 
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Research Agenda: 
• Steroid treatment for children with CAH should be optimized to preserve height potential and prevent long term effect of hyperandrogenism while avoiding ove
• The decision to treat PPP in girls with MAS should be individualized based on frequency of menses and effect on skeletal maturation. Letrozole and Tamoxifen are treatment 
options. 
• Boys with FMPP should receive combination therapy with a 3rd generation AI and an anti-androgen. Similar treatment regimen can be used for boys with MAS and PPP.
• PPP associated with gonadal or extra gonadal tumors typically resolves with treatment of primary tumor. 
• CPP can develop in children with various forms of PPP, especially in those with advanced BA, and additional testing and treatment with a GnRHa may be necessary.
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Figure 1 
Simplified representation of adrenal steroid biosynthesis. Dotted arrows represent reactions that occur 
primarily in the gonads. 
3βHSD: 3β Hydroxysteroid dehydrogenase/isomerase 
StAR: steroidogenic acute regulatory protein, involved in the transfer of cholesterol from outer to the inner 
mitochondrial membrane where desmolase, a side chain cleavage enzyme, is located. 
 
 
• Studies to investigate the optimal steroid regimen for CAH are needed. 
• Trials to determine long term safety of AIs in the management of PPP are necessary. 
• The effects of combination therapy with 3rd generation AI and the selective antiandrogen bicalutamide on AH in children with FMPP should be documented. 
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Figure 2  
Severely virilized external genitalia in a 46, XX newborn with 21 OHse deficiency 
Figure 3 
Classic appearance of café-au-lait macules in a boy with MAS 
 
 
 
 
 
Table 1  
Summary of the various pharmacological agents studied in girls with MAS and PPP 
GV: growth velocity, BA: bone age, AI: aromatase inhibitor, FAH: final adult height 
 
Phamacological agent Action Number of 
patients 
(Study 
reference) 
 
Duration of 
treatment 
Efficacy Adverse effects 
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Cyproterone acetate antiandrogen Case reports 
 
(71, 72) 
 
 Decreased estradiol 
level 
No change in FAH 
Glucocorticoid effect in high 
doses 
Medroxyprogesterone 
acetate 
Progestin: inhibits 
gonadal 
steroidogenesis 
6 
(73) 
6-16 months Decreased vaginal 
bleeding 
Regression in breast 
development 
Continued rapid GV in 
half 
 
Ketoconazole P450 cytochrome 
inhibitor: inhibits 
adrenal and 
gonadal 
steroidogenesis 
2 
(32) 
12 months Cessation of menses 
Regression of signs of 
puberty 
Pruritis 
 
Testolactone 1st generation AI 12 
(35) 
6 months-5 
years 
Less efficacious 
overtime 
Decreased BA 
advancement but no 
change in FAH 
Mild GI upset 
Headaches 
Liver enzyme elevation 
Need for frequent 
dosing/compliance issues 
Fadrazole 2nd generation AI 16 
(34) 
12-33 months No changes in GV, 
rate of BA 
advancement or 
Adrenal insufficiency 
Abdominal pain  
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frequency of menses Muscle weakness 
 
Anastrozole 3rd generation AI 27 
(36) 
12 months No changes in GV, 
rate of BA 
advancement or 
frequency of menses 
None 
Letrozole 3rd generation AI 9 
(38)  
1-3 years Decreased vaginal 
bleeding 
Decreased GV and 
rate of BA 
advancement 
Increased ovarian volume 
and cyst size 
1 child with hemorrhagic 
cyst and ovarian torsion 
GI Symptoms 
Letrozole  28 
(37) 
6 months-10 
years 
Decreased rate of BA 
advancement 
Improved FAH 
None 
Tamoxifen Estrogen receptor 
modulator 
25 
(38, 39)  
12 months Decreased GV, and 
rate of BA 
advancement 
Decreased frequency 
of menses 
Increased ovarian and 
uterine volumes 
Tamoxifen  8 
(40) 
3-8 years Decreased frequency 
of menses 
Improved FAH 
None 
Fulvestrant Pure estrogen 30  12 months Decreased vaginal None  
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receptor 
antagonist 
(41) bleeding 
Decreased BA 
advancement 
 
 
 
 
 
 
 
 
Table 2  
Summary of the various pharmacological agents studied in FMPP 
GV: growth velocity, BA: bone age, AI: aromatase inhibitor, FAH: final adult height 
 
Pharmacological agent  Mode of action Number of 
patients 
(Study 
reference) 
Duration 
of 
treatment 
Efficacy Safety/ 
Limitations of 
the study 
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Medroxyprogesterone  Progestin: 
inhibits gonadal 
steroidogenesis 
2  
(74) 
 
5 years Decreased 
testosterone   
Decreased GV 
No FAH data 
Cyproterone acetate Anti-androgen Case reports  
(48, 52) 
 Decreased 
testosterone 
Decreased GV 
and BA 
advancement  
No effect on FAH 
None  
Ketoconazole P450 
cytochrome 
inhibitor: inhibits 
adrenal and 
gonadal 
steroidogenesis 
5  
(52) 
 
8 years Decreased 
testosterone 
Decreased GV 
and BA 
advancement 
Limited effect on 
FAH 
None 
Ketoconazole  5  
(75) 
 
5-10 years Decreased 
testosterone 
FAH similar to 
target height 
Mild transaminitis 
Increased ACTH 
Testolactone/spironolactone First generation 
AI/ weak 
androgen 
receptor blocker 
10 
(76) 
 
6 years Decreased GV 
and BA 
advancement 
Improved 
predicted AH 
No FAH data 
GI side effects  
Need for frequent 
dosing 
Testolactone (later changed to 
3rd generation 
AI)/spironolactone/GnRH 
agonist 
 28 
(54) 
7 years Improved FAH Mild GI side 
effects 
Bicalutamide/anastrozole 
(BATT study) 
Potent androgen 
receptor 
blocker/3rd 
generation AI 
14  
(56) 
 
1 year Decreased GV 
and BA 
advancement 
 
Gynecomastia 
Breast 
tenderness 
short term data  
Bicalutamide/anastrozole or 
letrozole 
Letrozole: 3rd 
generation AI 
2  
(57) 
4.5-5 
years 
Decreased GV 
and BA 
advancement 
Improved 
none 
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 predicted AH 
 
 
 
 
 
 
 
 
 
Bibliography 
1. Levine LS. Congenital adrenal hyperplasia. Pediatrics in review. 2000;21(5):159-70. 
*2. Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-
Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. The Journal of clinical 
endocrinology and metabolism. 2018;103(11):4043-88. 
3. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365(9477):2125-36. 
4. White PC, Grossberger D, Onufer BJ, et al. Two genes encoding steroid 21-hydroxylase are 
located near the genes encoding the fourth component of complement in man. Proceedings of the 
National Academy of Sciences of the United States of America. 1985;82(4):1089-93. 
5. White PC, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. Proceedings of 
the National Academy of Sciences of the United States of America. 1986;83(14):5111-5. 
6. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 
Endocrine reviews. 2000;21(3):245-91. 
*7. Eugster EA, Dimeglio LA, Wright JC, et al. Height outcome in congenital adrenal hyperplasia 
caused by 21-hydroxylase deficiency: a meta-analysis. The Journal of pediatrics. 2001;138(1):26-32. 
8. Pescovitz OH, Comite F, Cassorla F, et al. True precocious puberty complicating congenital 
adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. The Journal of 
clinical endocrinology and metabolism. 1984;58(5):857-61. 
9. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary 
syndrome in an unselected population. The Journal of clinical endocrinology and metabolism. 
2004;89(6):2745-9. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
25 
 
10. Chrousos GP, Loriaux DL, Mann DL, Cutler GB, Jr. Late-onset 21-hydroxylase deficiency 
mimicking idiopathic hirsutism or polycystic ovarian disease. Annals of internal medicine. 1982;96(2):143-
8. 
*11. Lekarev O, Lin-Su K, Vogiatzi MG. Infertility and Reproductive Function in Patients with 
Congenital Adrenal Hyperplasia: Pathophysiology, Advances in Management, and Recent Outcomes. 
Endocrinology and metabolism clinics of North America. 2015;44(4):705-22. 
12. Falhammar H, Nystrom HF, Ekstrom U, et al. Fertility, sexuality and testicular adrenal rest tumors 
in adult males with congenital adrenal hyperplasia. European journal of endocrinology. 2012;166(3):441-
9. 
13. Chaudhari M, Johnson EK, DaJusta D, Nahata L. Testicular adrenal rest tumor screening and 
fertility counseling among males with congenital adrenal hyperplasia. Journal of pediatric urology. 
2018;14(2):155 e1- e6. 
14. Smeets EE, Span PN, van Herwaarden AE, et al. Molecular characterization of testicular adrenal 
rest tumors in congenital adrenal hyperplasia: lesions with both adrenocortical and Leydig cell features. 
The Journal of clinical endocrinology and metabolism. 2015;100(3):E524-30. 
15. Levine LS, S.A O. Congenital Adrenal hyperplasia. Pescovitz OH, Walvoord E, editors. New 
Jersey: Humana Press; 2007. 
16. Nebesio TD, Renbarger JL, Nabhan ZM, et al. Differential effects of hydrocortisone, prednisone, 
and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital 
adrenal hyperplasia. International journal of pediatric endocrinology. 2016;2016:17. 
17. Leslie JA, Cain MP, Rink RC. Feminizing genital reconstruction in congenital adrenal hyperplasia. 
Indian journal of urology : IJU : journal of the Urological Society of India. 2009;25(1):17-26. 
18. Sturm RM, Durbin-Johnson B, Kurzrock EA. Congenital adrenal hyperplasia: current surgical 
management at academic medical centers in the United States. The Journal of urology. 2015;193(5 
Suppl):1796-801. 
19. Berenbaum SA, Bailey JM. Effects on gender identity of prenatal androgens and genital 
appearance: evidence from girls with congenital adrenal hyperplasia. The Journal of clinical 
endocrinology and metabolism. 2003;88(3):1102-6. 
20. Dacou-Voutetakis C, Karidis N. Congenital adrenal hyperplasia complicated by central precocious 
puberty: treatment with LHRH-agonist analogue. Annals of the New York Academy of Sciences. 
1993;687:250-4. 
21. Guven A, Nurcan Cebeci A, Hancili S. Gonadotropin releasing hormone analog treatment in 
children with congenital adrenal hyperplasia complicated by central precocious puberty. Hormones. 
2015;14(2):265-71. 
22. Lin-Su K, Vogiatzi MG, Marshall I, et al. Treatment with growth hormone and luteinizing hormone 
releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. The 
Journal of clinical endocrinology and metabolism. 2005;90(6):3318-25. 
23. Lin-Su K, Harbison MD, Lekarev O, et al. Final adult height in children with congenital adrenal 
hyperplasia treated with growth hormone. The Journal of clinical endocrinology and metabolism. 
2011;96(6):1710-7. 
24. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in 
the McCune-Albright syndrome. The New England journal of medicine. 1991;325(24):1688-95. 
*25. Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of 
the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. The 
Journal of pediatrics. 1993;123(4):509-18. 
26. Haddad N, Eugster E. An update on the treatment of precocious puberty in McCune-Albright 
syndrome and testotoxicosis. Journal of pediatric endocrinology & metabolism : JPEM. 2007;20(6):653-
61. 
27. Casey R; Boyce A EA, et al. Implications for the Future of Pediatric and Adolescent Girls With 
McCune-Albright Syndrome: Long Term Obstetrical and Gynecologic Outcomes2015; Oral Abstracts / J 
Pediatr Adolesc Gynecol 28  [e32 p.]. 
28. Boyce AM, Chong WH, Shawker TH, et al. Characterization and management of testicular 
pathology in McCune-Albright syndrome. The Journal of clinical endocrinology and metabolism. 
2012;97(9):E1782-90. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
26 
 
29. Coutant R, Lumbroso S, Rey R, et al. Macroorchidism due to autonomous hyperfunction of Sertoli 
cells and G(s)alpha gene mutation: an unusual expression of McCune-Albright syndrome in a prepubertal 
boy. The Journal of clinical endocrinology and metabolism. 2001;86(4):1778-81. 
30. Wasniewska M, De Luca F, Bertelloni S, et al. Testicular microlithiasis: an unreported feature of 
McCune-Albright syndrome in males. The Journal of pediatrics. 2004;145(5):670-2. 
31. Nabhan ZM, West KW, Eugster EA. Oophorectomy in McCune-Albright syndrome: a case of 
mistaken identity. Journal of pediatric surgery. 2007;42(9):1578-83. 
32. Syed FA, Chalew SA. Ketoconazole treatment of gonadotropin independent precocious puberty 
in girls with McCune-Albright syndrome: a preliminary report. Journal of pediatric endocrinology & 
metabolism : JPEM. 1999;12(1):81-3. 
33. Vermeer LM, Isringhausen CD, Ogilvie BW, Buckley DB. Evaluation of Ketoconazole and Its 
Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of 
Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. 
Drug metabolism and disposition: the biological fate of chemicals. 2016;44(3):453-9. 
34. Nunez SB, Calis K, Cutler GB, Jr., et al. Lack of efficacy of fadrozole in treating precocious 
puberty in girls with the McCune-Albright syndrome. The Journal of clinical endocrinology and 
metabolism. 2003;88(12):5730-3. 
35. Feuillan PP, Jones J, Cutler GB, Jr. Long-term testolactone therapy for precocious puberty in girls 
with the McCune-Albright syndrome. The Journal of clinical endocrinology and metabolism. 
1993;77(3):647-51. 
36. Mieszczak J, Lowe ES, Plourde P, Eugster EA. The aromatase inhibitor anastrozole is ineffective 
in the treatment of precocious puberty in girls with McCune-Albright syndrome. The Journal of clinical 
endocrinology and metabolism. 2008;93(7):2751-4. 
*37. Estrada A, Boyce AM, Brillante BA, et al. Long-term outcomes of letrozole treatment for 
precocious puberty in girls with McCune-Albright syndrome. European journal of endocrinology. 
2016;175(5):477-83. 
38. Feuillan P, Calis K, Hill S, et al. Letrozole treatment of precocious puberty in girls with the 
McCune-Albright syndrome: a pilot study. The Journal of clinical endocrinology and metabolism. 
2007;92(6):2100-6. 
39. Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-
Albright syndrome: a multicenter trial. The Journal of pediatrics. 2003;143(1):60-6. 
*40. de GBPC, Kuperman H, Cabral de Menezes-Filho H, et al. Tamoxifen Improves Final Height 
Prediction in Girls with McCune-Albright Syndrome: A Long Follow-Up. Hormone research in paediatrics. 
2015;84(3):184-9. 
41. Sims EK, Garnett S, Guzman F, et al. Fulvestrant treatment of precocious puberty in girls with 
McCune-Albright syndrome. International journal of pediatric endocrinology. 2012;2012(1):26. 
42. Tessaris D, Matarazzo P, Mussa A, et al. Combined treatment with bicalutamide and anastrozole 
in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome. Endocrine journal. 
2012;59(2):111-7. 
43. Rousseau-Merck MF, Misrahi M, Atger M, et al. Localization of the human luteinizing 
hormone/choriogonadotropin receptor gene (LHCGR) to chromosome 2p21. Cytogenetics and cell 
genetics. 1990;54(1-2):77-9. 
*44. Shenker A, Laue L, Kosugi S, et al. A constitutively activating mutation of the luteinizing hormone 
receptor in familial male precocious puberty. Nature. 1993;365(6447):652-4. 
45. Nabhan ZM, Eugster E. Testotoxicosis with an episodic course: an unusual case within a series. 
Endocrine Practice [Internet]. 2018. 
46. Holland FJ, Kirsch SE, Selby R. Gonadotropin-independent precocious puberty ("testotoxicosis"): 
influence of maturational status on response to ketoconazole. The Journal of clinical endocrinology and 
metabolism. 1987;64(2):328-33. 
47. Reiter EO, Brown RS, Longcope C, Beitins IZ. Male-limited familial precocious puberty in three 
generations. Apparent Leydig-cell autonomy and elevated glycoprotein hormone alpha subunit. The New 
England journal of medicine. 1984;311(8):515-9. 
48. Bertelloni S, Baroncelli GI, Lala R, et al. Long-term outcome of male-limited gonadotropin-
independent precocious puberty. Hormone research. 1997;48(5):235-9. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
27 
 
49. Egli CA, Rosenthal SM, Grumbach MM, et al. Pituitary gonadotropin-independent male-limited 
autosomal dominant sexual precocity in nine generations: familial testotoxicosis. The Journal of 
pediatrics. 1985;106(1):33-40. 
50. Martin MM, Wu SM, Martin AL, et al. Testicular seminoma in a patient with a constitutively 
activating mutation of the luteinizing hormone/chorionic gonadotropin receptor. European journal of 
endocrinology. 1998;139(1):101-6. 
51. Leschek EW, Chan WY, Diamond DA, et al. Nodular Leydig cell hyperplasia in a boy with familial 
male-limited precocious puberty. The Journal of pediatrics. 2001;138(6):949-51. 
52. Almeida MQ, Brito VN, Lins TS, et al. Long-term treatment of familial male-limited precocious 
puberty (testotoxicosis) with cyproterone acetate or ketoconazole. Clinical endocrinology. 2008;69(1):93-
8. 
53. Babovic-Vuksanovic D, Donaldson MD, Gibson NA, Wallace AM. Hazards of ketoconazole 
therapy in testotoxicosis. Acta paediatrica. 1994;83(9):994-7. 
*54. Leschek EW, Flor AC, Bryant JC, et al. Effect of Antiandrogen, Aromatase Inhibitor, and 
Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty. The 
Journal of pediatrics. 2017;190:229-35. 
55. Kreher NC, Pescovitz OH, Delameter P, et al. Treatment of familial male-limited precocious 
puberty with bicalutamide and anastrozole. The Journal of pediatrics. 2006;149(3):416-20. 
*56. Reiter EO, Mauras N, McCormick K, et al. Bicalutamide plus anastrozole for the treatment of 
gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot 
study (BATT). Journal of pediatric endocrinology & metabolism : JPEM. 2010;23(10):999-1009. 
57. Lenz AM, Shulman D, Eugster EA, et al. Bicalutamide and third-generation aromatase inhibitors 
in testotoxicosis. Pediatrics. 2010;126(3):e728-33. 
58. Schneider DT, Calaminus G, Harms D, Gobel U, German Maligne Keimzelltumoren Study G. 
Ovarian sex cord-stromal tumors in children and adolescents. The Journal of reproductive medicine. 
2005;50(6):439-46. 
59. Breen JL, Maxson WS. Ovarian tumors in children and adolescents. Clinical obstetrics and 
gynecology. 1977;20(3):607-23. 
60. Olivier P, Simoneau-Roy J, Francoeur D, et al. Leydig cell tumors in children: contrasting clinical, 
hormonal, anatomical, and molecular characteristics in boys and girls. The Journal of pediatrics. 
2012;161(6):1147-52. 
61. Johnstone G. Prepubertal gynaecomastia in association with an interstitial-cell tumour of the 
testis. British journal of urology. 1967;39(2):211-20. 
62. Cheville JC, Sebo TJ, Lager DJ, et al. Leydig cell tumor of the testis: a clinicopathologic, DNA 
content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors. The American journal of 
surgical pathology. 1998;22(11):1361-7. 
63. Young S, Gooneratne S, Straus FH, et al. Feminizing Sertoli cell tumors in boys with Peutz-
Jeghers syndrome. The American journal of surgical pathology. 1995;19(1):50-8. 
64. Hemminki A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cellular and 
molecular life sciences : CMLS. 1999;55(5):735-50. 
65. Aguirre D, Nieto K, Lazos M, et al. Extragonadal germ cell tumors are often associated with 
Klinefelter syndrome. Human pathology. 2006;37(4):477-80. 
66. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast 
cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-8. 
67. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-
specific manner to pediatric adrenal cortical carcinoma. Proceedings of the National Academy of 
Sciences of the United States of America. 2001;98(16):9330-5. 
68. Medeiros LJ, Weiss LM. New developments in the pathologic diagnosis of adrenal cortical 
neoplasms. A review. American journal of clinical pathology. 1992;97(1):73-83. 
69. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children 
with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(5):838-
45. 
70. Mayer SK, Oligny LL, Deal C, et al. Childhood adrenocortical tumors: case series and 
reevaluation of prognosis--a 24-year experience. Journal of pediatric surgery. 1997;32(6):911-5. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28 
 
71. Carani C, Pacchioni C, Baldini A, Zini D. Effects of cyproterone acetate, LHRH agonist and 
ovarian surgery in McCune-Albright syndrome with precocious puberty and galactorrhea. Journal of 
endocrinological investigation. 1988;11(6):419-23. 
72. Sorgo W, Kiraly E, Homoki J, et al. The effects of cyproterone acetate on statural growth in 
children with precocious puberty. Acta endocrinologica. 1987;115(1):44-56. 
73. Rao S, Colaco MP, Desai MP. McCune Albright Syndrome (MCAS): a case series. Indian 
pediatrics. 2003;40(1):29-35. 
74. Rosenthal SM, Grumbach MM, Kaplan SL. Gonadotropin-independent familial sexual precocity 
with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing 
hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. The Journal of 
clinical endocrinology and metabolism. 1983;57(3):571-9. 
*75. Soriano-Guillen L, Lahlou N, Chauvet G, et al. Adult height after ketoconazole treatment in 
patients with familial male-limited precocious puberty. The Journal of clinical endocrinology and 
metabolism. 2005;90(1):147-51. 
76. Leschek EW, Jones J, Barnes KM, et al. Six-year results of spironolactone and testolactone 
treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty 
onset. The Journal of clinical endocrinology and metabolism. 1999;84(1):175-8. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnenolone 
Cholesterol 
Progesterone 
17OH 
Pregnenolone 
Aldosterone 18OH 
Corticosterone 
DOC Corticosterone 
17OH 
Progesterone 
11 Deoxycortisol Cortisol 
DHEA 
Androstenedione Estrone 
Estradiol Testosterone 
StAR                    
20-22 Desmolase 
11β-hydroxylase 
17α-hydroxylase 
21-hydroxylase 3βHSD  18-oxidase 
aromatase 
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